#Vienna #Austria #CGM #diabetes #SIBIONICS

SiBionics and Its Innovative Diabetes Solutions

A New Era in Diabetes Management

On September 23, 2025, the European Association for the Study of Diabetes (EASD) held its 61st annual meeting in Vienna, where SiBionics presented its groundbreaking integrated solution for diabetes treatment, including its continuous glucose monitoring (CGM) system, CGM GS3, and continuous ketone monitoring (CKM) device, KS3. The event gathered prominent scientists and healthcare professionals, who praised SiBionics' innovative approach to diabetes management.

Highlights from EASD 2025

SiBionics coordinated a symposium titled "CGM + CKM for Enhanced Diabetes Care," which allowed international experts to share the latest scientific evidence and research findings concerning diabetes treatment technologies. Among the notable speakers were Prof. Linong Ji from Peking University People's Hospital and Prof. Stefano Genovese from Italy, who co-chaired the sessions. Additionally, esteemed experts, including Prof. Andrej Janež from Slovenia and Prof. Nina Jendrike from Germany, were present to contribute their insights.

The booths showcasing SiBionics’ latest technology drew considerable attention, as attendees were eager to learn about the technical benefits and clinical significance of these new devices. Not only did SiBionics demonstrate the capabilities of its CGM GS3, but the CKM KS3 also sparked interest, reflecting the company’s commitment to advancing diabetes care.

Achievements and Recognition

According to feasibility studies, SiBionics has not only met but exceeded various iCGM performance standards, with their products being recognized for high accuracy and clinical reliability. The GS3 has proven exceptional accuracy, especially in recognizing hypoglycemia, a critical aspect in supporting clinical decision-making and patient self-management. This feature showcases SiBionics' strong capacity for innovation in continuous monitoring technologies.

The Future of SiBionics

SiBionics has positioned itself as a leading figure in the realm of continuous monitoring technologies, being the only company globally to introduce the CKM into commercial markets. The company showcases robust research and development capabilities, alongside a forward-thinking vision that promises to continually expand its CXM product line. SiBionics is committed to supporting innovations that provide precise, high-quality solutions, ultimately improving diabetes management for individuals worldwide.

A Commitment to Personalized Healthcare

Founded in 2015, SiBionics operates out of Shenzhen, China, and Irvine, California. The company specializes in biosensor innovations and integrates technology to enhance healthcare delivery. With more than 500 employees, 25% of whom focus on research and development, SiBionics is dedicated to advancing personalized healthcare solutions based on data-driven insights.

As diabetes continues to pose challenges globally, innovative solutions like those from SiBionics hold the key to improving treatment outcomes for millions of patients and redefining the standards of diabetes management. Stay tuned as SiBionics continues to innovate and shape the future of diabetes care.